Crewe Advisors LLC Purchases New Position in IQVIA Holdings Inc. (NYSE:IQV)

Crewe Advisors LLC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 254 shares of the medical research company’s stock, valued at approximately $64,000.

Other institutional investors also recently made changes to their positions in the company. AdvisorNet Financial Inc grew its stake in shares of IQVIA by 327.6% in the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 95 shares in the last quarter. Rise Advisors LLC acquired a new position in shares of IQVIA during the 1st quarter worth approximately $31,000. Riverview Trust Co bought a new position in shares of IQVIA during the first quarter worth approximately $32,000. Activest Wealth Management acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $35,000. Finally, Covestor Ltd boosted its stake in shares of IQVIA by 45.3% in the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after buying an additional 48 shares during the period. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on IQV. Truist Financial lifted their price objective on IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday. Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and dropped their price target for the company from $266.00 to $242.00 in a research note on Wednesday. Morgan Stanley raised their target price on shares of IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday. The Goldman Sachs Group began coverage on shares of IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target for the company. Finally, StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Monday, July 15th. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $263.56.

IQVIA Trading Up 1.4 %

IQV stock traded up $3.28 during trading on Friday, hitting $235.57. The company had a trading volume of 224,342 shares, compared to its average volume of 1,084,391. The stock has a market cap of $42.94 billion, a PE ratio of 31.73, a PEG ratio of 2.24 and a beta of 1.49. The business has a 50-day moving average of $220.06 and a 200-day moving average of $229.30. The company has a current ratio of 0.85, a quick ratio of 0.88 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. The company had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. IQVIA’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.22 earnings per share. Research analysts predict that IQVIA Holdings Inc. will post 10.13 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.